Tacrolimus Loaded Cationic Liposomes for Dry Eye Treatment

Chen, Xiang; Wu, Jicheng; Lin, Xiankun; Wu, Xingdi; Yu, Xuewen; Wang, Ben; Xu, Wen

doi:10.3389/fphar.2022.838168

Cited by 30 publications

(22 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been proven that cationic liposomes are the most promising siRNA carriers with high load rates, biocompatibility, and biodegradability. Commonly used cationic lipids include DOTAP [ 94 ], trimethyl-2 chloride, 3-dioleoxypropyl ammonium (DOTMA) [ 95 ], 3β-[N- (N′, N′-dimethylaminoethyl) aminoformyl] CHO (DC-CHOl) [ 96 ], etc. However, the stability, membrane fusion, and transfection efficiency of liposomes alone are poor, so auxiliary lipids are often necessary.…”

Section: Sirna Nanocarriersmentioning

confidence: 99%

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review

Tong

Liu

Cao

et al. 2023

IJMS

View full text Add to dashboard Cite

Gene therapy has attracted much attention because of its unique mechanism of action, non-toxicity, and good tolerance, which can kill cancer cells without damaging healthy tissues. siRNA-based gene therapy can downregulate, enhance, or correct gene expression by introducing some nucleic acid into patient tissues. Routine treatment of hemophilia requires frequent intravenous injections of missing clotting protein. The high cost of combined therapy causes most patients to lack the best treatment resources. siRNA therapy has the potential of lasting treatment and even curing diseases. Compared with traditional surgery and chemotherapy, siRNA has fewer side effects and less damage to normal cells. The available therapies for degenerative diseases can only alleviate the symptoms of patients, while siRNA therapy drugs can upregulate gene expression, modify epigenetic changes, and stop the disease. In addition, siRNA also plays an important role in cardiovascular diseases, gastrointestinal diseases, and hepatitis B. However, free siRNA is easily degraded by nuclease and has a short half-life in the blood. Research has found that siRNA can be delivered to specific cells through appropriate vector selection and design to improve the therapeutic effect. The application of viral vectors is limited because of their high immunogenicity and low capacity, while non-viral vectors are widely used because of their low immunogenicity, low production cost, and high safety. This paper reviews the common non-viral vectors in recent years and introduces their advantages and disadvantages, as well as the latest application examples.

show abstract

Section: Sirna Nanocarriersmentioning

confidence: 99%

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review

Tong

Liu

Cao

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Tacrolimus is another widely used immunosuppressant for DED treatment. Biodegradable formulations of tacrolimus, such as cationic liposome [ 113 ] and thermoresponsive in situ gel formulations [ 114 ] have been developed to improve ocular retention, enhance corneal tacrolimus concentration, and decrease levels of reactive oxygen species and inflammatory factors associated with DED ( Table 1 ).…”

Section: Application Of Different Biodegradable Ocular Drug Delivery ...mentioning

confidence: 99%

Updates on Biodegradable Formulations for Ocular Drug Delivery

Tsung

Chen

2023

Pharmaceutics

View full text Add to dashboard Cite

The complex nature of the ocular drug delivery barrier presents a significant challenge to the effective administration of drugs, resulting in poor therapeutic outcomes. To address this issue, it is essential to investigate new drugs and alternative delivery routes and vehicles. One promising approach is the use of biodegradable formulations to develop potential ocular drug delivery technologies. These include hydrogels, biodegradable microneedles, implants, and polymeric nanocarriers such as liposomes, nanoparticles, nanosuspensions, nanomicelles, and nanoemulsions. The research in these areas is rapidly growing. In this review, we provide an overview of recent updates in biodegradable formulations for ocular drug delivery over the past decade. Additionally, we examine the clinical use of different biodegradable formulations in various ocular diseases. The aim of this review is to gain a deeper understanding of potential future trends in biodegradable ocular drug delivery systems and to raise awareness of their potential for practical clinical application as a means of providing new treatment options for ocular diseases.

show abstract

“…Liposomes are one of the most popular nanoparticulate drug delivery systems, which are characterized by nanosized artificial vesicles with single or multiple bilayer membranes and an aqueous core, formed by phospholipids and cholesterol [68,69]. Their limited immunogenicity and high biodegradability profiles are attributed to the phospholipids used, which are similar to lipids found in cell membranes [70,71]. Additionally, they show the capacity to load a wide range of therapeutic compounds of different physicochemical properties, from lipophilic compounds loaded in the lipid bilayers to hydrophilic drugs encapsulated in the aqueous core, and also ionic and amphiphilic molecules that can be loaded using cationic or anionic lipids [72,73].…”

Section: Liposomesmentioning

confidence: 99%

Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Ana

Gliszczyńska

García

et al. 2023

JPM

View full text Add to dashboard Cite

Oxidation of lipids and lipoproteins contributes to inflammation processes that promote the development of eye diseases. This is a consequence of metabolism dysregulation; for instance, that of the dysfunctional peroxisomal lipid metabolism. Dysfunction of lipid peroxidation is a critical factor in oxidative stress that causes ROS-induced cell damage. Targeting the lipid metabolism to treat ocular diseases is an interesting and effective approach that is now being considered. Indeed, among ocular structures, retina is a fundamental tissue that shows high metabolism. Lipids and glucose are fuel substrates for photoreceptor mitochondria; therefore, retina is rich in lipids, especially phospholipids and cholesterol. The imbalance in cholesterol homeostasis and lipid accumulation in the human Bruch’s membrane are processes related to ocular diseases, such as AMD. In fact, preclinical tests are being performed in mice models with AMD, making this area a promising field. Nanotechnology, on the other hand, offers the opportunity to develop site-specific drug delivery systems to ocular tissues for the treatment of eye diseases. Specially, biodegradable nanoparticles constitute an interesting approach to treating metabolic eye-related pathologies. Among several drug delivery systems, lipid nanoparticles show attractive properties, e.g., no toxicological risk, easy scale-up and increased bioavailability of the loaded active compounds. This review analyses the mechanisms involved in ocular dyslipidemia, as well as their ocular manifestations. Moreover, active compounds as well as drug delivery systems which aim to target retinal lipid metabolism-related diseases are thoroughly discussed.

show abstract

Tacrolimus Loaded Cationic Liposomes for Dry Eye Treatment

Cited by 30 publications

References 61 publications

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review

Updates on Biodegradable Formulations for Ocular Drug Delivery

Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Contact Info

Product

Resources

About